Australia’s Therapeutic Goods Administration released new requirements for ‘sartan’ blood pressure medicines.

TGA urged sponsors to take measures to avoid the presence of N-nitroso impurities in their medicines and to implement rigorous testing to identify the presence of the impurities.

The agency is providing a two-year transition period for sponsors to make changes to their manufacturing processes and to implement adequate testing methods.